Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Andera Partners

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 193
Average round size
info
The average size of a deal this fund participated in
$26M
Portfolio companies 135
Rounds per year 2.72
Lead investments 48
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.30
Exits 48
Key employees 28
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Medical Device
Summary

In 1953 was created Andera Partners, which is appeared as VC. The fund was located in Europe if to be more exact in France. The main department of described VC is located in the Paris.

We also calculated 28 valuable employees in our database.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Andera Partners, startups are often financed by Neomed Management, Omnes Capital, Ysios Capital. The meaningful sponsors for the fund in investment in the same round are Omnes Capital, Idinvest Partners, Gimv. In the next rounds fund is usually obtained by Neomed Management, VI Partners AG, Omnes Capital.

The real fund results show that this VC is 20 percentage points more often commits exit comparing to other companies. Comparing to the other companies, this Andera Partners performs on 0 percentage points more the average number of lead investments. The top amount of exits for fund were in 2015. The fund is constantly included in 7-12 investment rounds annually. The important activity for fund was in 2015. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - France. Among the various public portfolio startups of the fund, we may underline Vivoryon Therapeutics, AM Pharma, Arvelle Therapeutics The fund has specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 11-15 years to get the investment from the fund. Among the most successful fund investment fields, there are Manufacturing, Health Diagnostics.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Andera Partners:
Typical Co-investors
Andera Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Andera Partners:

Funds with similar focus

Funds from France
Funds with similar focus located in France:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

ENYO Pharma

Biopharma
Biotechnology
Medical
$46M03 Jan 2024 Lyon, Auvergne-Rhône-Alpes, France

Nouscom

Biotechnology
Genetics
Health Care
Therapeutics
$79M14 Nov 2023 Basel, Basel-City, Switzerland

Dualyx

Biotechnology
Health Care
Medical
$47M15 May 2023 Ghent, Oost-Vlaanderen, Belgium

Evommune

Biotechnology
Life Science
$50M26 Apr 2023 California, United States

Ariceum Therapeutics

Health Care
Medical
Therapeutics
$26M18 Apr 2023 Berlin, Berlin, Germany

BioVentrix

Biotechnology
Health Care
Medical Device
Monitoring Equipment
Surgical Devices
$48M13 Apr 2023 California, United States

Grey Wolf Therapeutics

Biotechnology
Health Care
Therapeutics
$54M26 Jan 2023 Oxford, England, United Kingdom

SoniVie

Health Care
Health Diagnostics
Medical
$60M09 Jan 2023 Rosh Ha'ayin, HaMerkaz, Israel

Tricares

Health Care
Medical
Medical Device
$55M16 Sep 2022 Paris, Ile-de-France, France
News
Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Andera Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 193
Average round size 26M
Rounds per year 2.72
Peak activity year 2017
Lead investments 48
Follow on index 0.30
Exits 48
Group Appearance index 0.69

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

ENYO Pharma

Biopharma
Biotechnology
Medical
$46M03 Jan 2024 Lyon, Auvergne-Rhône-Alpes, France

Nouscom

Biotechnology
Genetics
Health Care
Therapeutics
$79M14 Nov 2023 Basel, Basel-City, Switzerland

Dualyx

Biotechnology
Health Care
Medical
$47M15 May 2023 Ghent, Oost-Vlaanderen, Belgium

Evommune

Biotechnology
Life Science
$50M26 Apr 2023 California, United States

Ariceum Therapeutics

Health Care
Medical
Therapeutics
$26M18 Apr 2023 Berlin, Berlin, Germany

BioVentrix

Biotechnology
Health Care
Medical Device
Monitoring Equipment
Surgical Devices
$48M13 Apr 2023 California, United States

Grey Wolf Therapeutics

Biotechnology
Health Care
Therapeutics
$54M26 Jan 2023 Oxford, England, United Kingdom

SoniVie

Health Care
Health Diagnostics
Medical
$60M09 Jan 2023 Rosh Ha'ayin, HaMerkaz, Israel

Tricares

Health Care
Medical
Medical Device
$55M16 Sep 2022 Paris, Ile-de-France, France
Crunchbase icon

Content report

The following text will be sent to our editors: